Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › pegozafermin

pegozafermin

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of pegozafermin

2 trials tracked of pegozafermin.

2Trials tracked
0Phase 3 & 4
0Recruiting
0With published results
Phase distribution
Phase 2 2
  1. Phase 2 Study to Explore the Efficacy and Safety of BIO89-100 (Pegozafermin) in Participants With Severe Hypertriglyceridemia Completed
  2. Phase 2 A Multiple Ascending Dose Study of Pegozafermin in Participants With Biopsy Confirmed Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) and at High Risk of NASH Completed

Showing the 2 most-cited and recently-updated of 2 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Review of triglyceride-lowering therapies for metabolic dysfunction-associated steatotic liver disease
Drug Pipeline Sys. Review
Review of triglyceride-lowering therapies for metabolic dysfunction-associated steatotic liver disease New Hope for Fatty Liver Disease Targets Hidden Triglyceride Problem
This narrative review synthesizes evidence on triglyceride-lowering therapies for metabolic dysfunction-associated steatotic liver disease. …
• Lowering triglycerides may directly heal fatty liver damage • Helps millions with metabolic syndrome and stubborn liver fat • Most treatme…
Frontiers May 12, 2026
Network meta-analysis finds pegozafermin, OCA, and resmetirom outperform placebo for MASLD fibrosis improvement
Gastroenterology Meta-analysis
Network meta-analysis finds pegozafermin, OCA, and resmetirom outperform placebo for MASLD fibrosis improvement New Liver Treatments Show Real Promise in Reversing Scarring
A systematic review and network meta-analysis of 10,119 adult patients with MASLD found pegozafermin, obeticholic acid (OCA), and resmetirom…
For the first time, doctors have clear evidence that new medications can help reverse the dangerous liver scarring caused by common fatty li…
Apr 10, 2026